ASTM E2525-22

Overview

ASTM E2525-22: Standard Test Method for Evaluation of the Effect of Nanoparticulate Materials on the Formation of Mouse Granulocyte-Macrophage Colonies provides a comprehensive, quantitative framework for assessing the impact of nanoparticulate materials on bone marrow stem cells. This in vitro test specifically evaluates how these nanoparticles affect granulocyte-macrophage colony-forming units (CFU-GM) derived from murine bone marrow. Decreasing CFU-GM counts can indicate the toxicity of a substance to bone marrow, a critical endpoint in preclinical safety and immunotoxicology assessment, particularly for drug development and nanoparticle evaluation for systemic administration in medical applications.

The procedure outlined in ASTM E2525-22 is a vital component of the preclinical characterization of nanomaterials, helping stakeholders identify potential myelosuppressive effects-where drugs or nanoformulations may suppress the immune system via bone marrow toxicity.

Key Topics

• CFU-GM Assay: Measures the effect of nanoparticulate materials on hematopoietic stem cells’ ability to form granulocyte and macrophage colonies, which are essential for immune system function.
• Nanoparticle Toxicity Evaluation: Detects toxicity or stimulation induced by nanoparticles in comparison with established positive and negative controls.
• Stem Cell Sensitivity: Focuses on pluripotential hematopoietic stem cells, which may be especially sensitive to nanoparticles, making this assay relevant for new medical materials.
• Myelosuppression Assessment: Used to reveal immunosuppression risk, supporting regulatory compliance and product safety.
• In Vitro Preclinical Screening: Allows early-stage screening of materials intended for systemic administration before animal or human studies.

Applications

ASTM E2525-22 is widely applicable across multiple sectors that develop or evaluate nanoparticulate materials, including:

• Pharmaceutical Development: Used by pharmaceutical companies to screen new drugs, especially those formulated with nanoparticulate delivery systems, for their effects on immune cell production and bone marrow health.
• Nanomedicine Research: Enables researchers to determine the safety profile of novel nanomaterials, aiding the translation of nanotechnology-based therapies into clinical use.
• Medical Device Evaluation: Assists medical device manufacturers in documenting the biocompatibility of nanoscale components or coatings for regulatory submissions.
• Toxicology and Safety Laboratories: Provides contract research organizations, government, and academic labs with a standardized approach to assess bone marrow toxicity of new substances or materials.
• Regulatory Compliance: Supports submissions to regulatory agencies by providing robust, internationally-recognized safety data for systemic administration products.

Employing this standard test method streamlines the comparison of different nanoparticulate materials under consistent, reproducible conditions, improving both safety and innovation outcomes.

Related Standards

For a holistic assessment of nanomaterial and particle safety, ASTM E2525-22 should be used alongside the following standards:

• ASTM F1903: Practice for Testing for Cellular Responses to Particles in vitro-focuses on macrophage responses, complementing the stem cell analysis in E2525-22.
• ANSI/AAMI ST72: Bacterial Endotoxins-Test Methodologies, Routine Monitoring, and Alternatives to Batch Testing-addresses sterility and pyrogenicity in biological assays.
• ASTM E56 Series: Standards from ASTM Committee E56 on Nanotechnology, which address various aspects of nanomaterial characterization and safety.

By following ASTM E2525-22, organizations benefit from increased confidence in the biological safety evaluation of nanoparticulate materials, supporting innovation, compliance, and risk management in the fast-evolving field of nanotechnology.

Keywords: ASTM E2525, nanoparticulate materials, CFU-GM, bone marrow toxicity, immunosuppression, myelosuppression, preclinical testing, stem cells, nanomedicine safety, in vitro assay, granulocyte-macrophage colony, pharmaceutical nanotechnology.